학술논문
AVB500, a receptor tyrosine kinase AXL inhibitor, has improved therapeutic efficacy in combination with bevacizumab compared to bevacizumab alone in uterine serous cancer mouse model
Document Type
Abstract
Author
Source
In Gynecologic Oncology October 2020 159 Supplement 1:77-77
Subject
Language
ISSN
0090-8258